{"id":56972,"date":"2024-02-27T17:16:42","date_gmt":"2024-02-27T17:16:42","guid":{"rendered":"https:\/\/medsname.com\/ezedoc\/"},"modified":"2026-08-28T11:51:18","modified_gmt":"2026-08-28T11:51:18","slug":"ezedoc","status":"publish","type":"product","link":"https:\/\/medsbase.com\/fi\/product\/ezedoc\/","title":{"rendered":"Ezedoc"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 0 0 24px 0; border-radius: 4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin: 0 0 8px 0; font-size: 16px; font-weight: bold;\">\u26a1 Quick Answer \u2014 What is Ezedoc?<\/h3>\n<p style=\"margin: 0;\"><strong>Ezedoc<\/strong> sis\u00e4lt\u00e4\u00e4 <strong>ezetimibe<\/strong> (10 mg), <strong>kolesterolin imeytymisen est\u00e4j\u00e4<\/strong> joka est\u00e4\u00e4 NPC1L1-kuljetinta ohutsuolessa. Se on <strong>go-to add-on therapy when a statin alone doesn\u2019t get LDL to target<\/strong>. On its own, ezetimibe lowers LDL-C by about 17\u201322%. Added to a statin, it produces an additional ~20\u201325% LDL reduction, totaling a 55\u201360% fall \u2014 equivalent to doubling the statin dose without the dose-related muscle or liver side effects. The <strong>IMPROVE-IT<\/strong> trial (18,144 patients post-ACS) proved that adding ezetimibe to simvastatin further reduces cardiovascular events. Dose: 10\u00a0mg once daily, any time, with or without food. Generally very well-tolerated \u2014 mild GI upset, occasional myalgia, rare transaminase elevation. Avoid in severe hepatic impairment.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Mit\u00e4 saat MedsBasen kautta:<\/strong> WHO-GMP sertifioitu valmistaja \u00b7 Hienotunteinen pakkaus \u00b7 Maailmanlaajuinen toimitus \u00b7 1 400+ varmennettua <a href=\"https:\/\/medsbase.com\/fi\/reviews\/\">asiakasarviota<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Jokainen tilaus on katettuna meid\u00e4n <a href=\"https:\/\/medsbase.com\/fi\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy -politiikkamme piiriin<\/strong><\/a> \u2014 jos l\u00e4hetyksesi ei saavu 20 arkip\u00e4iv\u00e4ss\u00e4, l\u00e4het\u00e4mme uuden.<\/p>\n<h3>Miksi tilata MedsBasesta<\/h3>\n<p>Geneeriset l\u00e4\u00e4kkeemme tulevat WHO-GMP-sertifioiduilta valmistajilta ja toimitetaan maailmanlaajuisesti huomaamattomassa, neutraalissa pakkauksessa \u2013 l\u00e4\u00e4kkeen nimi ei n\u00e4y paketin ulkopuolella. Korttimaksut k\u00e4sitell\u00e4\u00e4n s\u00e4\u00e4deltyjen maksujenk\u00e4sittelij\u00f6iden kautta (tiliotteiden kuvaukset sis\u00e4lt\u00e4v\u00e4t s\u00e4\u00e4dellyn korttimaksujenk\u00e4sittelij\u00e4n \u2013 ei koskaan \u201cMedsBase\u201d tai l\u00e4\u00e4kkeen nime\u00e4). Hyv\u00e4ksymme my\u00f6s kryptovaluutat ja SEPA-pankkisiirrot. Jokainen tilaus on turvattu uusintatoimituspolitiikallamme.<\/p>\n<h2 class=\"wp-block-heading\">Mik\u00e4 on Ezedoc?<\/h2>\n<p>Ezedoc on suun kautta nautittava lipidien alentamiseen tarkoitettu l\u00e4\u00e4ke, joka sis\u00e4lt\u00e4\u00e4 <strong>ezetimibe<\/strong> (10 mg) ja jonka on valmistanut WHO-GMP-sertifioitu valmistaja. Pakkauskoot 30, 60, 90 tai 180 tablettia. Etsetimibi on ensimm\u00e4inen ja ainoa <strong>kolesterolin imeytymisen est\u00e4j\u00e4<\/strong> -luokan l\u00e4\u00e4ke. Alkuper\u00e4isvalmiste: <strong>Zetia \/ Ezetrol<\/strong> (Merck, 2002).<\/p>\n<p>Ezetimibe is a mainstay of second-line lipid management \u2014 the first choice when you need more LDL reduction than a tolerated statin dose provides, or when a patient cannot tolerate higher statin doses. It is also the most common partner in fixed-dose combinations (simvastatin\/ezetimibe = Inegy\/Vytorin; rosuvastatin\/ezetimibe = various).<\/p>\n<h2 class=\"wp-block-heading\">Mihin Ezedoccia k\u00e4ytet\u00e4\u00e4n?<\/h2>\n<ul>\n<li><strong>Prim\u00e4\u00e4rinen hyperkolesterolemia<\/strong> \u2014 as add-on to a statin when LDL is not at goal on the maximum tolerated statin dose<\/li>\n<li><strong>Statiini-intoleranssi<\/strong> \u2014 as monotherapy or with a very low statin dose when a full statin dose causes muscle or liver problems<\/li>\n<li><strong>Perinn\u00f6llinen hyperkolesterolemia<\/strong> (heterozygous and homozygous) \u2014 in combination with statin<\/li>\n<li><strong>Toissijainen ehk\u00e4isy akuutin sepelvaltimotapahtuman j\u00e4lkeen<\/strong> \u2014 add to statin to further reduce CV events (IMPROVE-IT trial)<\/li>\n<li><strong>Sitosterolemia<\/strong> \u2014 a rare genetic condition where ezetimibe is disease-modifying<\/li>\n<\/ul>\n<p>Ezetimibe is weak as a monotherapy (~17% LDL reduction) compared to a statin (~30\u201360%); it is most powerful as an add-on.<\/p>\n<h2 class=\"wp-block-heading\">Kuinka Ezedoc toimii?<\/h2>\n<p>Ezetimibi est\u00e4\u00e4 selektiivisesti <strong>Niemann-Pick C1-Like 1 (NPC1L1) -kuljettajaproteiinia<\/strong> suoliston l\u00e4heisimm\u00e4ss\u00e4 ohutsuolessa olevilla enterosyytteill\u00e4. NPC1L1 vastaa ravinnosta ja sappinesteest\u00e4 per\u00e4isin olevan kolesterolin imeytymisest\u00e4 suolen limakalvosta enterosyyttiin.<\/p>\n<p>Kun NPC1L1 on estetty:<\/p>\n<ul>\n<li><strong>Suoliston kolesterolin imeytyminen v\u00e4henee noin 54 %<\/strong><\/li>\n<li><strong>Maksan kolesterolivarastot v\u00e4henev\u00e4t<\/strong> koska v\u00e4hemm\u00e4n kolesterolia saavuttaa maksan<\/li>\n<li><strong>LDL-reseptorien m\u00e4\u00e4r\u00e4 lis\u00e4\u00e4ntyy<\/strong> on hepatocytes \u2014 the liver pulls more LDL out of the blood<\/li>\n<li><strong>Plasma LDL-C falls by 17\u201322%<\/strong> yksin\u00e4\u00e4n k\u00e4ytettyn\u00e4; jopa 25 % lis\u00e4vaikutus statiinien kanssa yhdistettyn\u00e4<\/li>\n<li>HMG-CoA-reduktaasin aktiivisuus (statiinien kohde) pysyy muuttumattomana<\/li>\n<\/ul>\n<p>Koska ezetimibi ja statiinit vaikuttavat <strong>t\u00e4ydent\u00e4viin reitteihin<\/strong> (absorption vs synthesis), their effects are additive. Statins reduce LDL synthesis; ezetimibe reduces LDL absorption\/input. Together they drop LDL more than either can alone, without adding to each other\u2019s side-effect profile.<\/p>\n<p>Tulostiedot: <strong>IMPROVE-IT-tutkimus<\/strong> (2015) osoitti, ett\u00e4 ezetimibin lis\u00e4\u00e4minen simvastatiiniin syd\u00e4ninfarktin j\u00e4lkeisill\u00e4 potilailla v\u00e4hensi yhdistetty\u00e4 CV-tapahtumaa 6,4 % (NNT 50 7 vuoden aikana), vahvistaen, ett\u00e4 LDL:n alentaminen johtaa todellisiin tapahtumien v\u00e4henemiseen.<\/p>\n<h2 class=\"wp-block-heading\">Annostelu ja k\u00e4ytt\u00f6<\/h2>\n<p><strong>Vakioannos:<\/strong> 10\u00a0mg once daily at any time of day, with or without food.<\/p>\n<ul>\n<li>Ota samaan aikaan p\u00e4ivitt\u00e4in s\u00e4\u00e4nn\u00f6llisyyden vuoksi.<\/li>\n<li>Can be taken at the same time as a statin or spaced out \u2014 no timing interaction.<\/li>\n<li>Miss a dose \u2014 take it as soon as you remember unless close to the next; do not double up.<\/li>\n<li>Annosta ei tarvitse s\u00e4\u00e4t\u00e4\u00e4 munuaisten vajaatoiminnan tai liev\u00e4n\u2013kohtalan maksan vajaatoiminnan yhteydess\u00e4.<\/li>\n<li>Monitor lipid panel and ALT at baseline and 6\u20138 weeks after starting. Check CK only if symptoms.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Haittavaikutukset<\/h2>\n<p>Ezetimiibi on yksi parhaiten siedetyist\u00e4 lipidien alentajista. Haittavaikutukset ovat koeolosuhteissa l\u00e4hell\u00e4 lumel\u00e4\u00e4kkeen tasoa.<\/p>\n<p><strong>Yleiset (&lt; 5%):<\/strong><\/p>\n<ul>\n<li>Liev\u00e4 ripuli, ilmavaivat<\/li>\n<li>Ylempien hengitysteiden infektio, sivuontelotulehdus<\/li>\n<li>V\u00e4symys<\/li>\n<li>Nivels\u00e4rky<\/li>\n<\/ul>\n<p><strong>Ep\u00e4tavalliset:<\/strong><\/p>\n<ul>\n<li>Transaminase elevation \u2014 usually small; more common when combined with a statin<\/li>\n<li>Muscle pain, myalgia, myopathy \u2014 rare; primarily when combined with statin<\/li>\n<li>Yliherkkyys, angio\u00f6deema, ihottuma<\/li>\n<li>Pancreatitis \u2014 very rare<\/li>\n<li>Cholelithiasis \u2014 very rare<\/li>\n<li>Thrombocytopenia \u2014 very rare<\/li>\n<li>Rhabdomyolysis \u2014 exceedingly rare, almost always in combination with a statin<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">L\u00e4\u00e4keaineenvaihdunta<\/h2>\n<ul>\n<li><strong>Siklosporiini<\/strong> \u2014 significantly raises ezetimibe levels (and vice versa). Monitor cyclosporine levels; some guidance suggests avoiding.<\/li>\n<li><strong>Sappihapposekvestraattorit<\/strong> (cholestyramine, colestipol) \u2014 reduce ezetimibe absorption; take ezetimibe at least 2 hours before or 4 hours after.<\/li>\n<li><strong>Varfariini<\/strong> \u2014 occasional INR change reported; monitor when starting.<\/li>\n<li><strong>Statiinit<\/strong> \u2014 no adverse PK interaction; this combination is the therapeutic mainstay.<\/li>\n<li><strong>Fibraatit<\/strong> \u2014 fenofibrate\/ezetimibe combination is safe; gemfibrozil raises ezetimibe levels and is generally avoided.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Kenelle Ezedoc ei sovi?<\/h2>\n<ul>\n<li>Keskivaikea tai vaikea maksasairaus (kun yhdistet\u00e4\u00e4n statiiniin)<\/li>\n<li>Active liver disease or persistent transaminase elevation &gt; 3\u00d7 ULN<\/li>\n<li>Raskaus (kun yhdistet\u00e4\u00e4n statiiniin)<\/li>\n<li>Rintaruokinta<\/li>\n<li>Alle 10-vuotiaat lapset (riitt\u00e4m\u00e4t\u00f6n tutkimusaineisto)<\/li>\n<li>Tunnettu yliherkkyys ezetimiibille<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">S\u00e4ilytys<\/h2>\n<p>Store Ezedoc below 25\u00b0C in a dry place, in the original blister. Keep out of reach of children.<\/p>\n<h2 id=\"faqs\">Usein Kysytyt Kysymykset<\/h2>\n<h3 class=\"wp-block-heading\">Voinko ottaa Ezedocin statiinin sijasta?<\/h3>\n<p>Usually no. As monotherapy, ezetimibe lowers LDL by only ~17% \u2014 much less than a statin (30\u201360%). It is appropriate as monotherapy only for patients who cannot tolerate any statin at any dose. For most people, the best lipid-lowering strategy is statin first, ezetimibe added if LDL is still above target.<\/p>\n<h3 class=\"wp-block-heading\">Miten Ezedoc vertautuu statiiniannoksen kaksinkertaistamiseen?<\/h3>\n<p>Doubling a statin dose typically adds ~6% LDL reduction (the statin \u201crule of 6\u201d). Adding ezetimibe adds ~20\u201325% LDL reduction. <strong>Adding ezetimibe is 3\u20134\u00d7 more effective<\/strong> kuin statiiniannoksen kaksinkertaistaminen, ilman annokseen liittyv\u00e4\u00e4 lihasoireiden lis\u00e4\u00e4ntymist\u00e4. T\u00e4st\u00e4 syyst\u00e4 nykyaikaiset suositukset suosivat statiinin ja ezetimiibin yhdistelm\u00e4\u00e4 statiinin maksimiannoksen k\u00e4ytt\u00e4misen sijaan.<\/p>\n<h3 class=\"wp-block-heading\">V\u00e4hent\u00e4\u00e4k\u00f6 Ezedoc syd\u00e4nkohtauksia ja aivohalvauksia?<\/h3>\n<p>Yes \u2014 the IMPROVE-IT trial (18,144 post-ACS patients) showed adding ezetimibe to simvastatin reduced the composite endpoint of CV death, MI, unstable angina, revascularisation, or stroke by 6.4% over 7 years. This is the landmark evidence that LDL reduction beyond statins alone still translates into real cardiovascular benefit.<\/p>\n<h3 class=\"wp-block-heading\">Milloin minun tulisi ottaa Ezedoc?<\/h3>\n<p>Any time of day is fine. Unlike simvastatin (evening preferred), ezetimibe timing is not dose-dependent \u2014 pick a time you will remember consistently. Many patients take it at the same time as their statin.<\/p>\n<h3 class=\"wp-block-heading\">Aiheuttaako Ezedoc lihaskipua kuten stattiinit?<\/h3>\n<p>Harvoin. Ezetimiibi monoterapiana aiheuttaa placebotason lihasoireita. Kun sit\u00e4 yhdistet\u00e4\u00e4n statiiniin, se ei lis\u00e4\u00e4 merkitt\u00e4v\u00e4sti statiiniin liittyvi\u00e4 lihasoireita verrattuna pelkk\u00e4\u00e4n statiiniin.<\/p>\n<h3 class=\"wp-block-heading\">Mist\u00e4 voin ostaa Ezedocin verkosta?<\/h3>\n<p>Voit tilata Ezedocin (10 mg) MedsBasesta 30, 60, 90 tai 180 tabletin pakkauksissa. Toimitamme maailmanlaajuisesti huomaamattomissa pakkauksissa ja aidosta WHO-GMP-sertifioidun valmistajan varastosta.<\/p>\n<h2 class=\"wp-block-heading\">Aiheeseen liittyv\u00e4t kolesterolil\u00e4\u00e4kkeet<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/fi\/lipvas\/\">Lipvas \u2014 Atorvastatin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/fi\/crestor\/\">Crestor \u2014 Rosuvastatin 5\/10\/20 mg (AstraZeneca)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/fi\/rosuline\/\">Rosuline \u2014 Rosuvastatin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/fi\/atorvatin\/\">Atorvatin \u2014 Atorvastatin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/fi\/pivasta\/\">Pivasta \u2014 Pitavastatin (interaction-clean)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/fi\/lipicard\/\">Lipicard \u2014 Fenofibrate (for triglycerides)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/fi\/high-cholesterol-treatments\/\"><strong>Selaa kaikkia korkean kolesterolitason l\u00e4\u00e4kkeit\u00e4<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background: #fff3f3; border-left: 4px solid #d9534f; padding: 16px 20px; margin: 24px 0; border-radius: 4px;\"><strong>\u2695 Medical Disclaimer.<\/strong> T\u00e4m\u00e4 sivu on vain tiedottamistarkoituksessa eik\u00e4 korvaa p\u00e4tev\u00e4n terveydenhuollon ammattilaisen antamaa l\u00e4\u00e4ketieteellist\u00e4 neuvontaa. Selitt\u00e4m\u00e4t\u00f6n lihaskipu, ihon tai silmien keltastuminen tai vakava vatsakipu vaatii v\u00e4litt\u00f6m\u00e4\u00e4 l\u00e4\u00e4k\u00e4rin arviointia.<\/div>\n<h3 class=\"wp-block-heading\">Miksi tilata MedsBasesta<\/h3>\n<p>Ezedoc toimitetaan WHO-GMP-sertifioidun valmistajan kautta t\u00e4ydellisell\u00e4 COA-dokumentaatiolla. Toimitamme maailmanlaajuisesti yksinkertaisissa, huomaamattomissa pakkauksissa, ja jokainen tilaus on katettu <a href=\"\/fi\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy -politiikkamme piiriin<\/a>. Your statement descriptor when paying by card shows the regulated payment processor (a regulated card-payment processor), never \u201cMedsBase\u201d or any medication name.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Aiheeseen liittyv\u00e4t vaihtoehdot<\/h3>\n<p>Muut tuotteet <strong>Krooniset sairaudet<\/strong> joita asiakkaat my\u00f6s katsovat:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/fi\/bencid\/\">Bencid<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/fi\/tiova-rotacaps\/\">Tiova Rotacaps<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/fi\/serobid-rotacaps\/\">Serobid Rotacaps<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/fi\/headset\/\">Kuuloke<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/fi\/xafinact\/\">Xafinact<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Alentaa kolesterolitasoja<br \/>\n\u2705 V\u00e4hent\u00e4\u00e4 syd\u00e4nsairauden riski\u00e4<br \/>\n\u2705 Est\u00e4\u00e4 ateroskleroosin<br \/>\n\u2705 L\u00e4\u00e4k\u00e4rin m\u00e4\u00e4r\u00e4\u00e4m\u00e4<br \/>\n\u2705 Suun kautta otettava vaihtoehto<\/p>\n<p><strong>Ezedoc<\/strong> sis\u00e4lt\u00e4\u00e4 <strong>Ezetimibe<\/strong>.<\/p>","protected":false},"featured_media":56973,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3953],"product_tag":[4210,4211],"class_list":{"0":"post-56972","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-high-cholesterol-treatments","9":"product_tag-ezedoc","10":"product_tag-ezetimibe","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/fi\/wp-json\/wp\/v2\/product\/56972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/fi\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/fi\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fi\/wp-json\/wp\/v2\/comments?post=56972"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fi\/wp-json\/wp\/v2\/media\/56973"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/fi\/wp-json\/wp\/v2\/media?parent=56972"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/fi\/wp-json\/wp\/v2\/product_brand?post=56972"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/fi\/wp-json\/wp\/v2\/product_cat?post=56972"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/fi\/wp-json\/wp\/v2\/product_tag?post=56972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}